PLAU

PLAU

PLAU Overview

Molecule Name
Urokinase plasminogen activator
Synonyms
Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs4
Highest Development StageApproved
Target Synonym
PLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC 3.4.21,EC:3.4.21.73,U-Plasminogen Activator,EC 3.4.21.73
Background
Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

PLAU Product List

Species
  • Human(2)
Tag
  • His Tag(2)
Host
  • HEK293(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • No(2)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
PLAU
Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
Human
HEK293
SDS-PAGE
Enzyme

$360.00

50ug
PLAU
Human PLAU / uPA Protein, His Tag
Human
HEK293
SDS-PAGE
ELISASPR

$320.00

50ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
tPA/HisproUK (Thrombolytic Science)TS-01Phase 2 ClinicalThrombolytic Science
Ischemic Stroke
Details
Upamostat Hydrogen SulphateWX-671; LH-011; RHB-107Phase 2 ClinicalWilex AG
Coronavirus Disease 2019 (COVID-19); Metastatic breast cancer; Pancreatic Neoplasms
Details
MicrolyseTGD-001Phase 2 ClinicalUniversity Medical Centre Utrecht, Netherlands
Ischemic Stroke; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia; Thrombotic Microangiopathies
Details
Recombinant annexin A5 (Annexin Pharmaceuticals)ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5)Phase 2 ClinicalAnnexin Pharmaceuticals AB
Anemia, Sickle Cell; Cardiovascular Diseases; Diabetic Retinopathy; Neoplasms; Retinal Vein Occlusion
Details
MSB-03MSB-03Phase 1 ClinicalMatriSys Bioscience Inc
Rosacea
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Urokinase biosimilar (Sedico)ApprovedSedicoAngikinaseEgyptThromboembolism; Myocardial Infarction; Pulmonary EmbolismSedico2014-01-01
Myocardial Infarction; Pulmonary Embolism; Thromboembolism
Details
TisokinaseAK-124ApprovedAsahi Kasei Corp, Kowa Dental Health Co LtdPlasvata, HapaseJapanMyocardial Infarction; Thrombosisnull1991-01-01
Myocardial Infarction; Thrombosis
Details
Urokinase biosimilar (Bharat Serums & Vaccines)U-FRAGApprovedBharat Serums And Vaccines Ltd
Pulmonary Embolism
Details
NasaruplaseGE-0943ApprovedMitsubishi Pharma CorpTomieze, ThrombolyseJapanMyocardial Infarction; Venous ThrombosisMitsubishi Pharma Corp1992-01-01
Myocardial Infarction; Venous Thrombosis
Details
Customer Reviews